IE
ANRO icon

Israel Englander’s Alto Neuroscience ANRO Stock Holding History

Israel Englander’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32,300
Closed -$370K – 6547
2024
Q3 		$370K Buy
+32,300
New +$395K ﹤0.01% 5058

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Israel Englander's ANRO Position: Q2 2026 in Review

Israel Englander reduced its Alto Neuroscience (ANRO) stake by 32% in Q2 2026, selling an estimated $6.1M and leaving 558,320 shares worth $14.7M. The position accounts for 0.01% of the portfolio, ranked #1914.

Israel Englander first reported a position in ANRO in Q1 2024 and has held it in 8 quarters since. The position peaked at $18.5M in Q1 2026. 113 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Israel Englander held 558,320 shares of Alto Neuroscience worth $14.7M as of Q2 2026.
  • Israel Englander sold 263,662 Alto Neuroscience shares in Q2 2026, an estimated $6.1M.
  • Alto Neuroscience made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1914 holding.
  • Israel Englander first reported a position in Alto Neuroscience in Q1 2024 and has held it in 8 quarters since.
  • Israel Englander's Alto Neuroscience position peaked at $18.5M in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.